NCT06080399View on ClinicalTrials.gov

Personality and Quality of Life Amelioration After Continuous Subcutaneous Apomorphine Infusion in Parkinson's Disease

RecruitingOBSERVATIONAL
Enrollment

70

Participants

Timeline

Start Date

February 15, 2024

Primary Completion Date

April 1, 2026

Study Completion Date

April 1, 2026

Conditions
Parkinson Disease
Interventions
OTHER

Continuous subcutaneous apomorphine infusion (CSAI)

the CSAI proposed in the usual healthcare pathway of each PD patients included

Trial Locations (10)

Unknown

RECRUITING

Chu de Lyon, Bron

RECRUITING

Hopital Gabriel Montpied, Clermont-Ferrand

RECRUITING

Chu de Grenoble, Grenoble

RECRUITING

Chu Limoges, Limoges

RECRUITING

Chu de Nancy, Nancy

RECRUITING

Chu de Nice, Nice

RECRUITING

Chu de Poitiers, Poitiers

RECRUITING

Chu de Rennes, Rennes

RECRUITING

Chu de Rouen, Rouen

RECRUITING

Chu de Toulouse, Toulouse

All Listed Sponsors
collaborator

ELIVIE France

UNKNOWN

collaborator

EVER Pharma France SAS

UNKNOWN

collaborator

NHC SAS, France

UNKNOWN

collaborator

Orkyn'

INDUSTRY

collaborator

ETPARK Association, Toulouse, France

UNKNOWN

lead

University Hospital, Toulouse

OTHER